Dr. Yong Tae Kwon, the CEO of AUTOTAC Bio, is our speaker for the latest series of the MSQ CEO Webinar , jointly hosted by MSQ Ventures and BioAroundWorld, with  Marc Estigarribia, the Managing Director of MSQ Ventures moderating the discussion. 

Innovative Drug Platforms: Targeted Protein Degradation Using Autophagy

AUTOTAC Bio, led by Dr. Yong Tae Kwon, is focused on developing innovative drugs by targeting protein aggregation. They use a protein target decomposition platform, which is a next-generation technology for drug development. Dr. Kwon, who has 30 years of experience in research on cellular degradation systems, discussed the role of the autophagy pathway in diseases such as cancer, neurodegenerative diseases, and rare conditions. 

During the webinar, Dr. Kwon presented scientific data demonstrating the efficacy of their drugs in animal models. The data showed significant improvements in disease symptoms and reductions in protein aggregates. The company has applied for clinical trials for different diseases and is seeking partnerships and investments to expand its reach. 

The webinar also highlighted the potential of this cutting-edge technology to revolutionize the field of drug development, with a focus on its effectiveness in treating neurodegenerative diseases and other conditions caused by protein aggregation. 

Follow https://msqventures.com/ for more updates on the latest therapeutic development trends and strategic biopharma partnerships/financing opportunities.